Luciferase reporter assay revealed that the FXR relative luciferase activity was significantly higher in the case of OA treatment in a dose-dependent manner, leading to angiotensin (Ang)-(1–7) upregulation, which, in turn, perturbs the development of atherosclerosis. This evidence concerns the gene NR1H4 and atherosclerosis.